Familial Hypophosphatemia

Familial Hypophosphatemia

National Organization for Rare Disorders, Inc.

Important

It is possible that the main title of the report Familial Hypophosphatemia is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.

Synonyms

  • hereditary type I hypophosphatemia (HPDR I)
  • hereditary type II hypophosphatemia (HPDR II)
  • hypophosphatemic D-resistant rickets I
  • hypophosphatemic D-resistant rickets II
  • phosphate diabetes
  • X-linked hypophosphatemia (XLH)
  • X-linked vitamin D-resistant rickets

Disorder Subdivisions

  • autosomal dominant hypophosphatemic rickets (ADHR)
  • autosomal recessive hypophosphatemic rickets
  • X-linked hypophosphatemic rickets

General Discussion

Familial hypophosphatemia is a rare inherited disorder characterized by impaired transport of phosphate and often altered vitamin-D metabolism in the kidneys. In addition, phosphate may not be well-absorbed in the intestines. The hypophosphatemia resulting from these impairments can lead to a skeletal defect called osteomalacia, which can be considered a softening of bones. Familial hypophosphatemia also results in rickets, a childhood bone disease with characteristic bow deformities of the legs, as well as growth plate abnormalities and progressive softening of the bone as occurs in osteomalacia. In adults, the growth plate is not present so that osteomalacia is the evident bone problem. In children, growth rates may be slower than normal, frequently resulting in short stature. Familial hypophosphatemia is most often inherited as an X-linked trait. However, autosomal dominant and recessive forms of familial hypophosphatemia occur.

Symptoms

Signs and symptoms of familial hypophosphatemia vary greatly, and are usually first noticed after eighteen months of age. Children often present with progressive bow deformities, short stature, and can develop bone pain. Adults may complain of osteomalacia-related pain, propensity to fracture, arthritis, or pain attributable to abnormal mineralization at the site of muscular attachments.



Infants may have an abnormally tall, narrow head (dolichocephaly), or abnormally early fusion of the skull bones (craniosynostosis). Toddlers may have an abnormal "waddling" walk (gait) due to abnormally bowed legs (genu varus). In some cases, the knees are bent inwards such that they are too close together (knock knees or genu valgum). Hip deformities in which the thighbone angles towards the center of the body (coxa vara) may occur. Affected individuals often reach a shorter adult height than would otherwise be expected. In older adults, narrowing of the spine (spinal stenosis), and abnormal side-to-side curvature of the spine (scoliosis) may occur.



Symptoms such as weakness and intermittent muscle cramps may also occur, although this is not a usual finding in childhood. Cases of familial hypophosphatemia may range from mild to severe. Some cases may have no noticeable symptoms while other cases may be marked by pain and/or stiffness of the back, hips, and shoulders possibly limiting mobility. In later adulthood calcification of tendons and ligaments, and the development of bone spurs or bony protrusions can further limit mobility and cause pain.



Dental problems such as decay and abscesses or late eruption of teeth may develop in individuals with familial hypophosphatemia. In addition, affected individuals may experience enamel defects and an increased frequency of cavities (caries). In some cases, hearing impairment due to malformation of the inner ears (sensorineural hearing loss) may also be present.

Causes

In most cases, familial hypophosphatemia is inherited as a dominant X-linked trait, however variant forms may be inherited as an autosomal dominant or recessive trait.



In contrast to most X-linked disorders, which are recessive, X-linked dominant disorders are evident in a female with one normal X chromosome and one affected X chromosome.



X-linked familial hypophosphatemia (XLH) is caused by disruption or changes (mutations) of the PHEX gene located on the short arm (p) of the X chromosome (Xp22.2-22.1).* The PHEX protein is a member of an enzyme family of proteins, but at present it is not clear why the loss of a functional PHEX protein results in hypophosphatemic rickets. Individuals with XLH have been found to have elevated circulating levels of a novel growth factor called FGF23, and this factor has been shown to act on the kidney to result in excessive urinary excretion of phosphate. The mechanism by which the elevated FGF23 levels occur in the setting of PHEX dysfunction is also not understood.



* [Chromosomes are found in the nucleus of all body cells. They carry the genetic characteristics of each individual. Pairs of human chromosomes are numbered from 1 through 22, with an unequal 23rd pair of X and Y chromosomes for males and two X chromosomes for females. Each chromosome has a short arm designated as "p" and a long arm identified by the letter "q". Chromosomes are further subdivided into bands that are numbered. For example, "chromosome Xp22.2-22.1" refers to bands 22.2 through 22.1 on the short arm of chromosome X.]



Similarly, autosomal dominant familial hypophosphatemia (ADHR) may be caused by specific changes (mutations) of the FGF23 (Fibroblast Growth Factor 23) gene located on the short arm (p) of chromosome 12 (12p13.3). These changes result in a variant type of FGF23 that persists for longer than normal periods of time in the body, and can result in elevated FGF23 blood levels.



In familial hypophosphatemia, symptoms occur, at least in part, because of an impaired ability of the kidneys to retain phosphate. If the blood levels of phosphate become abnormally low, bone mineralization becomes impaired, thereby weakening the bones and leading to osteomalacia and bowed bones.



In addition there is a second renal abnormality in XLH and ADHR related to the activation of vitamin D. Active vitamin D formation is required for the body to maintain a normal handling of calcium, another important mineral important to bones. Both of these abnormalities of kidney function that of phosphate conservation and of vitamin D activation are mediated by the high levels of circulating FGF23.

Affected Populations

XLH may affect males and females in equal numbers. Cases affecting males have been said to be more severe than those affecting females, but this issue is controversial as a great variation in degree of severity exists. XLH occurs in one in 10,000 to 20,000 individuals. More recent estimates suggest that the figure may be as high as one in 20,000. XLH is the most common form of heritable rickets in the United States. The related disorder, ADHR, is encountered far less frequently.

Standard Therapies

Treatment of familial hypophosphatemia is symptomatic and supportive. Treatment consists of providing phosphate as well as an activated vitamin-D metabolite such as calcitriol. This treatment must be carefully monitored to prevent excess blood or urinary calcium levels. Vitamin-D compounds do not cure the disorder completely, but help the body retain phosphate and help with preventing the complications of too much secretion of a hormone called parathyroid hormone or PTH. Phosphate enhances the bone healing, but also does not completely cure the disease.



Treatment of affected individuals with this combination of vitamin D and phosphate may result in several side effects, including calcium deposits in the kidneys (nephrocalcinosis), excess levels of calcium in the blood (hypercalcemia), and excess levels of calcium in the urine (hypercalciuria).



Covering teeth with sealants has been suggested as a preventive measure for the spontaneous abscesses associated with familial hypophosphatemia. Genetic counseling may be of benefit for affected individuals and their families.

Investigational Therapies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.



For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:



Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov



For information about clinical trials sponsored by private sources, contact:

www.centerwatch.com



For information about clinical trials conducted in Europe, contact:

https://www.clinicaltrialsregister.eu/

References

JOURNAL ARTICLES

Bergwitz C, Jüppner H. FGF23 and syndromes of abnormal renal phosphate handling. Adv Exp Med Biol. 2012;728:41-64.



Gattineni J, Baum M. Genetic disorders of phosphate regulation. Pediatr Nephrol. 2012;27(9):1477-87.



Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia. J Bone Min Res. 26:1381-1388, 2011.



Pettifor JM. What's new in hypophosphataemic rickets? Eur J Pediatr. 2008;167(5):493-9.

Bielesz B, et al. Renal phosphate loss in hereditary and acquired disorders of bone mineralization. Bone. 2004;35(6):1229-39.



Rowe PS. The wrickkened pathways of FGF23, MEPE aand PHEX. Critical Reviews in Oral Biology & Medicine. 2004;15(5):264-81.



Holm IA, et al. Familial hypophosphatemia and related disorders. In: Pediatric Bone; Biology & Diseases. Glorieux FH, et a., eds. San Diego, CA: Academic Press. 2003. 603-31.



Jan de Beur SM, Levine MA. Molecular pathogenesis of hypophosphatemic rickets. J Clin Endocrin. & Metabl. 2002;87(6):2467-73.



DiMeglio LA. Econs MJ. Hypophosphatemic rickets. Reviews in Endocrine & Metabolic Disorders. 2001; 2(2):165-73.



Garg RK, et al., Hypophosphatemic rickets: easy to diagnose, difficult to treat. Indian J Pediatr. 1999;66:849-57.



Goodman JR, et al., Dental problems associated with hypophosphatemic vitamin D resistant rickets. Int J Paediatr Dent. 1998;8:19-28.



INTERNET

Carpenter TO. Primary disorders of phosphate metabolism. In: WWW.ENDOTEXT.ORG, version of September 20, 2010, (Ed: DeGroot L; Section Ed: Singer F), published by MDTEXT.COM, INC, S. Dartmouth, MA. Available at: http://www.endotext.org/parathyroid/parathyroid10/parathyroidframe10.htm Accessed:January 29, 2013.



McKusick VA., ed. Online Mendelian Inheritance in Man (OMIM). Baltimore. MD: The Johns Hopkins University; Available at: http://www.ncbi.nlm.nih.gov/omim Entry No:307800; Last Update:5/24/11. Entry No:193100; Last Update:10/4/10. Entry No:241520; Last Update:9/27/12. Entry No:241530; Last Update:11/29/12. Accessed January 29, 2013.

Resources

March of Dimes Birth Defects Foundation

1275 Mamaroneck Avenue

White Plains, NY 10605

Tel: (914)997-4488

Fax: (914)997-4763

Tel: (888)663-4637

Email: Askus@marchofdimes.com

Internet: http://www.marchofdimes.com



NIH/National Institute of Diabetes, Digestive & Kidney Diseases

Office of Communications & Public Liaison

Bldg 31, Rm 9A06

31 Center Drive, MSC 2560

Bethesda, MD 20892-2560

Tel: (301)496-3583

Email: NDDIC@info.niddk.nih.gov

Internet: http://www2.niddk.nih.gov/



XLH Network Inc.

911 Central Ave., #161

Albany, NY 12206

Email: Jim.Walker@XLHNetwork.org

Internet: http://www.xlhnetwork.org



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/



Madisons Foundation

PO Box 241956

Los Angeles, CA 90024

Tel: (310)264-0826

Fax: (310)264-4766

Email: getinfo@madisonsfoundation.org

Internet: http://www.madisonsfoundation.org



For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use . How this information was developed to help you make better health decisions.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.